

NOV. 7. 2005 3:48PM

AVENTIS US PAT DEPT **RECEIVED**
CENTRAL FAX CENTER

NO. 9607 P. 3

NOV 07 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: **P. Morris**

In re Application of
Bono-Combie et al.

Art Unit: **1625**

Application No.: **10/773,073**

Filed: **February 5, 2004**

Title: **USE OF 4-SUBSTITUTED
TETRAHYDROPYRIDENES FOR
MAKING MEDICINES ACTING ON
TGF-β1**

Telefacsimile Certificate

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

November 7, 2005

Date of transmission

Della Combie

Signature

RESPONSE TO OFFICE COMMUNICATION

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication mailed June 17, 2005 in the above-referenced application, Applicants elect Group III, claim 21 drawn to a method for treating pathologies linked to an abnormal apoptotic activity to be prosecuted. Applicants further elect prion diseases as the specific disease.

A request for a four-month extension of time and the required fee accompany this amendment, extending the period of reply to November 17, 2005. The Commissioner is authorized to charge any additional fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Prior to examination, please amend the claims as set forth in the listing of claims beginning on page 2 of this paper.